

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LIFE HEALTHCARE GROUP LIMITED

蓮和醫療健康集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 928)

GRANT OF WAIVER FROM STRICT COMPLIANCE WITH RULE 13.46(2)(a) OF THE LISTING RULES

Reference is made to (i) the announcement of Life Healthcare Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 27 June 2022 in relation to, among other things, the delay in publication of FY2022 Audited Annual Results of the Group; (ii) the announcement of the Company dated 30 June 2022 in relation to the publication of the FY2022 unaudited annual results; (iii) the announcement of the Company dated 19 July 2022 in relation to the date of board meeting scheduled on 29 July 2022 for the purpose of, among other things, approving the FY2022 Audited Annual Results; and (iv) the announcement of the Company dated 25 July 2022 in relation to further delay in publication of FY2022 Audited Annual Results, delay in publication of FY2022 annual report and postponement of board meeting (collectively, the “**Announcements**”). Capitalised terms used herein, unless otherwise defined, shall have the same meanings as those defined in the Announcements.

As disclosed in the Announcements, the Company’s auditing process for FY2022 has continuously been adversely affected due to the continuing implementation of the COVID-19 pandemic prevention and control quarantine measures and restrictions in certain cities in mainland China, especially Beijing where the Company’s head office and accounting department are located. The audit procedures for the FY2022 Audited Annual Results have not yet been completed, which is primarily attributable to the practical difficulties encountered in obtaining the required information relating to audit procedures including but not limited to fund receipt record, interview with suppliers, physical inspection of motor vehicles and their licences and obtain bank confirmations.

As additional time is required by the Company to provide the requisite information set out above for review by the Auditors in order to complete the audit procedures. The Company expects to publish FY2022 Audited Annual Results by 31 August 2022 and publish the FY2022 annual report by 9 September 2022.

GRANT OF WAIVER

Pursuant to Rule 13.46(2)(a) of the Listing Rules, the Company is required to despatch the FY2022 annual report not less than 21 days before the date of its annual general meeting and in any event not more than four months after the end of the financial year to which they relate, i.e. on or before 31 July 2022.

An application has been made by the Company to the Stock Exchange for waiver from strict compliance with the requirements of Rule 13.46(2)(a) of the Listing Rules in relation to the delay in publication of the FY2022 annual report.

The Stock Exchange has granted to the Company on 2 August 2022, a waiver from strict compliance with Rule 13.46(2)(a) of the Listing Rules on the basis that the Company will publish the FY2022 annual report on or before 9 September 2022 (the “**Waiver**”). The Waiver may be withdrawn or changed by the Stock Exchange if the Company’s situation changes.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
LIFE HEALTHCARE GROUP LIMITED
Pang Zhen
Executive Director

Hong Kong, 2 August 2022

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. Yuan Limin (*Chief Executive Officer*)
Mr. Pang Zhen
Mr. Man Wai Lun
Mr. Huang Zhifang

Independent non-executive Directors:

Mr. Liu Xinghua
Mr. Wang Yang
Mr. Chan Man Kiu